PERCHERON THERAPEUTICS LIMITED — Director's Dealing 2012

Jul 23, 2012

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.	Amended 01/01/11
Name of Entity:	Antisense Therapeutics Limited (ASX:ANP)
ABN:	41 095 060 745

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Mr Mark Diamond
Date of Last Notice:	7th May 2012

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or Indirect Interest	Direct
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.	-
Date of change	24th July 2012
No. of securities held prior to changeClass	DirectIndirectTotal	Shares3,439,818-3,439,818	Options5,812,460-5,812,460
Number acquired	Ordinary Shares
	Direct	Sharesa) 3,000,000	Options-
		b)812,460
	Indirect	-	-
	Total	3,812,460	-

+ See chapter 19 for defined terms.

Number disposed		Shares	Options
	Direct	-	a) 3,000,000
			b)812,460
	Indirect	-	-
	Total	-	3,812,460
Value/ConsiderationNote: If consideration is non-cash, provide details and estimatedvaluation	a)Nil cents per share as per 2008 EmployeeOption Planb)1.1 cents per share
No. of securities held after change		Shares	Options
	Direct	7,252,278	2,000,000
	Indirect	-	-
	Total	7,252,278	2,000,000
Nature of changeExample: on-market trade, off-market trade, exercise of options,Exercise of Optionsissue of securities under dividend reinvestment plan, participation inbuy-back

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder	N/A
(if issued securities)
Date of change	N/A
No. and class of securities to whichinterest related prior to changeNote: Details are only required for acontract in relation to which the interesthas changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, providedetails and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or	No
contracts detailed above traded during
a +closed period where prior written
clearance was required?
If so, was prior written clearance
provided to allow the trade to proceed	N/A
during this period?
If prior written clearance was provided,
on what date was this provided?	N/A

The CFO Solution 02/05/2012

+ See chapter 19 for defined terms.